TRL1068
Phase 2Small molecule
TRL1068 is one of 5 small molecule programs targeting Prosthetic-joint Infection. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Prosthetic-Joint Infection
#DrugCompanyPhaseTrials
1Acanya
PfizerApproved
Phage Therapy
AAdaptive Phage Therapeutics, Inc.
Phase 2
TRL1068
TTrellis Bioscience LLC
Phase 2
Tedizolid Phophate
Merck & Co.Preclinical
PLG0206
PPeptilogics
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TRL1068. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTrellis Bioscience LLC